ATE350067T1 - Verfahren zur bestimmung der wirkungen von botulinum-toxinen - Google Patents

Verfahren zur bestimmung der wirkungen von botulinum-toxinen

Info

Publication number
ATE350067T1
ATE350067T1 AT02773168T AT02773168T ATE350067T1 AT E350067 T1 ATE350067 T1 AT E350067T1 AT 02773168 T AT02773168 T AT 02773168T AT 02773168 T AT02773168 T AT 02773168T AT E350067 T1 ATE350067 T1 AT E350067T1
Authority
AT
Austria
Prior art keywords
determining
effects
methods
botulinum toxins
disclosed
Prior art date
Application number
AT02773168T
Other languages
English (en)
Inventor
James M Holland
Edward Chow
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE350067T1 publication Critical patent/ATE350067T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT02773168T 2001-08-03 2002-08-02 Verfahren zur bestimmung der wirkungen von botulinum-toxinen ATE350067T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30998801P 2001-08-03 2001-08-03
US10/208,165 US6984375B2 (en) 2001-08-03 2002-07-29 Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles

Publications (1)

Publication Number Publication Date
ATE350067T1 true ATE350067T1 (de) 2007-01-15

Family

ID=26902958

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02773168T ATE350067T1 (de) 2001-08-03 2002-08-02 Verfahren zur bestimmung der wirkungen von botulinum-toxinen

Country Status (7)

Country Link
US (3) US6984375B2 (de)
EP (1) EP1411991B1 (de)
JP (1) JP4214053B2 (de)
AT (1) ATE350067T1 (de)
DE (1) DE60217357T2 (de)
ES (1) ES2278965T3 (de)
WO (1) WO2003015829A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6859652B2 (en) 2000-08-02 2005-02-22 Mobile Satellite Ventures, Lp Integrated or autonomous system and method of satellite-terrestrial frequency reuse using signal attenuation and/or blockage, dynamic assignment of frequencies and/or hysteresis
EP1316233B1 (de) 2000-08-02 2011-10-05 ATC Technologies, LLC Koordinierte Wiederverwendung von Frequenzen von einem irdischen System und einem Satellitensystem.
US7792488B2 (en) 2000-12-04 2010-09-07 Atc Technologies, Llc Systems and methods for transmitting electromagnetic energy over a wireless channel having sufficiently weak measured signal strength
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US8949033B2 (en) 2006-04-28 2015-02-03 The Chemo-Sero-Therapeutic Research Institute Method for quantification of neurotoxin
WO2009036334A1 (en) * 2007-09-14 2009-03-19 Corventis, Inc. Adherent multi-sensor device with empathic monitoring
US8506970B2 (en) * 2008-10-14 2013-08-13 Dt Scimed, Llc Dose and localization of botulinum toxins in skin and muscle
JP5703508B2 (ja) * 2009-07-09 2015-04-22 株式会社Ｕｂｅ科学分析センター 毒性試験法
US8940482B1 (en) * 2010-06-11 2015-01-27 Synaptic Research, Llc N-end rule protease activity indication methods and uses thereof
ES2653249T3 (es) 2011-09-29 2018-02-06 Cellsnap, Llc Composiciones y métodos para ensayos de toxigenicidad
AU2014301116B2 (en) 2013-06-28 2019-11-14 Merz Pharma Gmbh & Co. Kgaa Means and methods for the determination of the biological activity of Neurotoxin polypeptides in cells
US20190030118A1 (en) * 2017-07-27 2019-01-31 Ipsen Biopharm Limited Treatment of lower limb spasticity
US11752335B1 (en) 2018-02-07 2023-09-12 Mary Kay Inc. Method for determining facial muscle responses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5158976A (en) * 1990-10-29 1992-10-27 The Children's Medical Center Corporation Controlling glutamine/glutamate related neuronal injury
US6485413B1 (en) * 1991-04-29 2002-11-26 The General Hospital Corporation Methods and apparatus for forward-directed optical scanning instruments
US5548661A (en) * 1991-07-12 1996-08-20 Price; Jeffrey H. Operator independent image cytometer
US5314805A (en) * 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US6309883B1 (en) * 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
KR100544060B1 (ko) * 1997-07-15 2006-01-23 더 리젠트스 오브 더 유니버시티 오브 콜로라도 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도
ATE251463T1 (de) * 1998-04-29 2003-10-15 Allergan Inc Zusammensetzungen und methode zum verlängung der wirkung des clostridiumsneurotoxins
US6113915A (en) * 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6429189B1 (en) * 1999-12-10 2002-08-06 Botulinum Toxin Research Associates, Inc. Cytotoxin (non-neurotoxin) for the treatment of human headache disorders and inflammatory diseases
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) * 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
JP2004505278A (ja) * 2000-07-28 2004-02-19 シーワイティーワイシー　ヘルス　コーポレイション 乳管洗浄によって回収した乳管上皮細胞の細胞学的評価
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
WO2003000193A2 (en) * 2001-06-21 2003-01-03 Surromed, Inc. Covalent coupling of botulinum toxin with polyethylene glycol
AU2002318437A1 (en) * 2001-06-29 2003-03-03 Clinomics Biosciences, Inc. Evaluating neuropsychiatric diseases using a specimen-linked database
US6984375B2 (en) * 2001-08-03 2006-01-10 Allergan, Inc. Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles

Also Published As

Publication number Publication date
WO2003015829A3 (en) 2003-12-18
US20050019338A1 (en) 2005-01-27
DE60217357D1 (de) 2007-02-15
DE60217357T2 (de) 2007-11-15
JP4214053B2 (ja) 2009-01-28
US20070218005A1 (en) 2007-09-20
WO2003015829A2 (en) 2003-02-27
JP2005509145A (ja) 2005-04-07
EP1411991A2 (de) 2004-04-28
US7229605B2 (en) 2007-06-12
US20030026760A1 (en) 2003-02-06
US6984375B2 (en) 2006-01-10
ES2278965T3 (es) 2007-08-16
EP1411991B1 (de) 2007-01-03

Similar Documents

Publication Publication Date Title
ATE350067T1 (de) Verfahren zur bestimmung der wirkungen von botulinum-toxinen
ATE347898T1 (de) Botulinustoxine zur behandlung von priapismus
ATE255418T1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
FR2708358B1 (fr) Procédé de saisie d'une information confidentielle, terminal et système de vérification associés.
WO2002095356A3 (en) Methods and compositions for analyzing proteins
DK0773788T3 (da) Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
WO2002029611A3 (en) Method and apparatus for effectively performing linear transformations
ATE426858T1 (de) System und verfahren zum erkennen von bísartigem code
DK0839006T4 (da) Fremgangsmåde til stabilisering af proteiner i et surt miljø med et højester-pectin
ATE169171T1 (de) Verfahren zur erkennung von dienstwechselwirkungen in intelligenten netzwerken
DE60308654D1 (de) Ermittlung der auswirkung von einem clostridial toxin auf muskeln
WO2006071469A3 (en) Modulation of the neuroendocrine system as a therapy for amyotrophic lateral sclerosis
BR9709569B1 (pt) processo para ativação de proteìna desnaturada.
SE0103360D0 (sv) Object oriented data processing
ATE126830T1 (de) Verfahren zum nachweis von kleinzelligem carzinom und die verwendung von sequenzen, die acylpeptid- hydrolase codieren, für diesen zweck.
WO2005016233A3 (en) Botulinum neurotoxin b receptors and use thereof
DE69734586D1 (de) Retinoid-metabolisierendes protein
ATE541047T1 (de) Therapeutische monoklonale antikörper zur neutralisierung von botulinum neurotoxinen
ATE286405T1 (de) Verfahren zur verhütung der nebenwirkungen und unempfindlichkeit gegenüber therapeutischen verwendungen von toxinen
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
DE50208091D1 (de) Verfahren zur färbung keratinischer fasern
Tong et al. New Achromobacter collagenase and its immunological relationship with a vertebrate collagenase
WO2002012283A3 (en) Disintegrin homologs, zsnk10, zsnk11, and zsnk12
IL151564A0 (en) Potassium channel proteins
AU7269100A (en) Method for indirectly determining the blood-clotting status

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties